Just came in through my email - https://mymsaa.org/news/whats-new-in...paign=november
Highlighting:
*Ofatumumab Favorable Phase III result
*Mayzent
*Impact of extending Tysabri® dosing
*What’s the risk of “rebound” disease activity after stopping Gilenya
*Assessing Ocrevus® beyond clinical trials
*FDA approves Vumerity
*A tilt toward monoclonal antibody therapy as first-line MS treatment
*Further evidence supporting early initiation of disease-modifying therapy
And more worth reading!
Highlighting:
*Ofatumumab Favorable Phase III result
*Mayzent
*Impact of extending Tysabri® dosing
*What’s the risk of “rebound” disease activity after stopping Gilenya
*Assessing Ocrevus® beyond clinical trials
*FDA approves Vumerity
*A tilt toward monoclonal antibody therapy as first-line MS treatment
*Further evidence supporting early initiation of disease-modifying therapy
And more worth reading!
Comment